We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Cancer-Associated Circular RNAs Catalogued Across Tumors

By LabMedica International staff writers
Posted on 18 Feb 2019
Circular RNA is a type of RNA which, unlike the better known linear RNA, forms a covalently closed continuous loop, i.e., in circular RNA the 3' and 5' ends normally present in an RNA molecule have been joined together.

Circular ribonucleic acids (circRNAs) are an intriguing class of RNA due to their covalently closed structure, high stability, and implicated roles in gene regulation. More...
Scientists have begun to catalogue and have started characterizing circRNAs found across cancer types, including proposed circRNA markers in the urine of prostate cancer patients.

A team of scientists from the University of Michigan (Ann Arbor, MI, USA) used exome capture and RNA sequencing to profile circRNAs in more than 800 tumors, cell line, or pooled normal samples assessed for the Michigan Oncology Sequencing Center (MI-ONCOSEQ) program. The analyses led to nearly 129,000 circRNAs in 40 cancer types, which they compared to more than 60,000 circRNAs previously compiled in the CircBase database.

Along with circRNA expression data for more than two dozen matched tumor-normal pairs, the team's cancer-associated circRNA collection known as MiOncoCirc, helped the team focus in on circRNAs associated with metastatic castration-resistant prostate cancer or aggressive neuroendocrine prostate cancer cases, as well as potential circRNA biomarkers found in urine samples from prostate cancer patients in general.

The team used Agilent SureSelect exon capture probes to target nearly 21,000 genes and more than 334,000 exons in cDNA from 868 clinical samples, cell lines, and pooled normal tissue samples, following by sequencing with Illumina technology and identifying candidate circRNAs with an analytical pipeline called CIRCexplorer. When the team compared and validated this method against established Ribo-Zero sequencing and exoribonuclease RNase R-based enrichment approaches in a prostate cancer cell line, it found that the exome capture approach appeared to pick up some circRNAs missed by Ribo-Zero, while maintaining "circular-to-linear ratios" that cannot be gleaned with the RNase R method.

The investigators used MiOncoCirc and identified candidate circRNAs to serve as biomarkers for prostate cancer and were able to detect circRNAs in urine. They further detected a novel class of circular transcripts, termed read-through circRNAs that involved exons originating from different genes. MiOncoCirc will serve as a valuable resource for the development of circRNAs as diagnostic or therapeutic targets across cancer types. The study was published on February 7, 2019, in the journal Cell.

Related Links:
University of Michigan


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.